WallStreetZenWallStreetZen

NASDAQ: VRNA
Verona Pharma PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VRNA

Based on 5 analysts offering 12 month price targets for Verona Pharma PLC.
Min Forecast
$36.00+12.46%
Avg Forecast
$39.40+23.09%
Max Forecast
$50.00+56.2%

Should I buy or sell VRNA stock?

Based on 5 analysts offering ratings for Verona Pharma PLC.
Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VRNA stock forecasts and price targets.

VRNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-10-03
lockedlocked$00.00+00.00%2024-10-01
lockedlocked$00.00+00.00%2024-07-22
lockedlocked$00.00+00.00%2024-06-28Find Out Why
lockedlocked$00.00+00.00%2024-04-16Find Out Why

1 of 1

Forecast return on equity

Is VRNA forecast to generate an efficient return?
Company
1,521.64%
Industry
-752.51%
Market
49.24%
VRNA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VRNA forecast to generate an efficient return on assets?
Company
589.82%
Industry
26.49%
VRNA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VRNA earnings per share forecast

What is VRNA's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$2.07
Avg 2 year Forecast
-$1.58
Avg 3 year Forecast
$2.28

VRNA revenue forecast

What is VRNA's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$7.6M
Avg 2 year Forecast
$77.4M
Avg 3 year Forecast
$475.5M

VRNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRNA$32.01$39.40+23.09%Strong Buy
GERN$4.32$7.21+66.99%Strong Buy
PTGX$44.37$52.83+19.07%Strong Buy
ZLAB$26.36$38.00+44.16%Strong Buy
KYMR$43.06$49.43+14.79%Buy
View Top Biotech Stocks

Verona Pharma Stock Forecast FAQ

Is Verona Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: VRNA) stock is to Strong Buy VRNA stock.

Out of 5 analysts, 4 (80%) are recommending VRNA as a Strong Buy, 1 (20%) are recommending VRNA as a Buy, 0 (0%) are recommending VRNA as a Hold, 0 (0%) are recommending VRNA as a Sell, and 0 (0%) are recommending VRNA as a Strong Sell.

If you're new to stock investing, here's how to buy Verona Pharma stock.

What is VRNA's earnings growth forecast for 2024-2026?

(NASDAQ: VRNA) Verona Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.7%.

Verona Pharma's earnings in 2024 is -$125,448,000.On average, 4 Wall Street analysts forecast VRNA's earnings for 2024 to be -$1,345,254,179, with the lowest VRNA earnings forecast at -$1,455,733,991, and the highest VRNA earnings forecast at -$1,299,762,492. On average, 4 Wall Street analysts forecast VRNA's earnings for 2025 to be -$1,025,187,666, with the lowest VRNA earnings forecast at -$1,143,790,993, and the highest VRNA earnings forecast at -$779,857,495.

In 2026, VRNA is forecast to generate $1,481,729,241 in earnings, with the lowest earnings forecast at -$415,923,997 and the highest earnings forecast at $3,379,382,479.

What is VRNA's revenue growth forecast for 2024-2026?

(NASDAQ: VRNA) Verona Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.63%.

Verona Pharma's revenue in 2024 is $0.On average, 4 Wall Street analysts forecast VRNA's revenue for 2024 to be $4,963,143,076, with the lowest VRNA revenue forecast at $1,566,213,803, and the highest VRNA revenue forecast at $8,123,515,575. On average, 4 Wall Street analysts forecast VRNA's revenue for 2025 to be $50,313,806,065, with the lowest VRNA revenue forecast at $23,688,171,417, and the highest VRNA revenue forecast at $76,231,070,156.

In 2026, VRNA is forecast to generate $309,021,781,879 in revenue, with the lowest revenue forecast at $168,969,123,960 and the highest revenue forecast at $449,074,439,798.

What is VRNA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VRNA) forecast ROA is 589.82%, which is higher than the forecast US Biotechnology industry average of 26.49%.

What is VRNA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year VRNA price target, the average VRNA price target is $39.40, with the highest VRNA stock price forecast at $50.00 and the lowest VRNA stock price forecast at $36.00.

On average, Wall Street analysts predict that Verona Pharma's share price could reach $39.40 by Oct 3, 2025. The average Verona Pharma stock price prediction forecasts a potential upside of 23.09% from the current VRNA share price of $32.01.

What is VRNA's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: VRNA) Verona Pharma's current Earnings Per Share (EPS) is -$1.60. On average, analysts forecast that VRNA's EPS will be -$2.07 for 2024, with the lowest EPS forecast at -$2.24, and the highest EPS forecast at -$2.00. On average, analysts forecast that VRNA's EPS will be -$1.58 for 2025, with the lowest EPS forecast at -$1.76, and the highest EPS forecast at -$1.20. In 2026, VRNA's EPS is forecast to hit $2.28 (min: -$0.64, max: $5.20).

What is VRNA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VRNA) forecast ROE is 1,521.64%, which is considered strong.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.